Jasper Therapeutics (JSPR) investor relations material

Recent merger and pipeline overview

• Completed a merger with Kira Pharmaceuticals, creating a company with multiple immunology assets, including two in clinical development and a third close behind.

• Lead asset KP-104 (vensobafusp) is a dual-functional complement inhibitor with positive phase II data in PNH and plans for an end-of-phase II FDA meeting next year.

• Briquilimab, an anti-KIT antibody, is being developed for SCID transplant patients and has orphan and rare pediatric disease designations, with a pre-BLA meeting planned for next year.

• KP-701, a bispecific antibody targeting CD79B and CD32B, aims to induce B cell anergy for autoantibody diseases and is nearing IND/CTA filing.

• A C5 long-acting program was out-licensed to Mirador as part of the merger.

Clinical data and competitive positioning

• KP-104 phase II in PNH showed all patients had at least a 2 g/dL hemoglobin increase, 89% normalized hemoglobin, and 100% transfusion-free status.

• Phase III trials for KP-104 are planned, with studies in both naive and C5a-experienced PNH patients, pending FDA discussions in the first half of next year.

• KP-104's dual mechanism offers both alternative and terminal complement pathway inhibition, potentially providing superior efficacy and safety compared to existing agents.

• The market for complement inhibitors continues to grow, with opportunities for new agents offering improved protection and transfusion independence.

Renal and other indications

• A renal basket study for KP-104 is underway, starting with 18 IgA nephropathy patients, with interim data expected later this year and plans to expand to C3G, FSGS, and other indications.

• Dosing intervals of Q4 or Q8 weeks are being explored for renal patients, with proof of concept and dosing guidance as key goals.

• Future development in IgA nephropathy and other renal diseases will depend on competitive data and proof of concept results.